Clinical trials: Cocaine Smoking
Cocaine Withdrawal, Cocaine Smoking
Use of Intranasal Oxytocin During Detoxification of Crack Cocaine
This study investigated whether adding oxytocin nasal spray to usual inpatient treatment could reduce withdrawal, anxiety, and depressive symptoms in women hospitalized for cocaine detoxification.
- Conditions
- Cocaine Withdrawal, Cocaine Smoking, Cocaine-Related Disorders
- Trial name
- NCT04306354
- Testing
- Oxytocin nasal spray, Conventional Inpatient Treatment
- Where
- Brazil
- Volunteers
- 84 people
- Sponsor
- Pontificia Universidade Católica do Rio Grande do Sul
Asperger's Disorder, Asperger Disorder
QAIAx (AIhealth4U) - AI Smart Health Cities: Microcity Enclave Program (Quantum AI/AGI Agency a/k/a AI City Hall Project - UPSTO App Nos. 64/074,526, 64/063,557, 64/105,164, 63/903,181, 63/729,428, 64/125,360)
BRIEF SUMMARY A. "What is the purpose of this study?" BACKGROUND. The QAIAx clinical trial (Quantum AI/AGI Public Health Agency), known operationally as the "AI City Hall Project," represents a landmark intergovernmental research…
- Conditions
- Asperger's Disorder, Asperger Disorder, Autism Disorder, Autism
- Trial name
- QAIAx (NCT07661823)
- Testing
- AI City Hall Project (AIhealth4u - Public Health Central), AI City Hall Project (QAIAx Microcity A - AI Public Health Central)
- Where
- United States
- Volunteers
- 1,000,000 people, healthy volunteers welcome
- Sponsor
- Veterans Recovery Network Inc.
Cocaine Dependence, Methamphetamine Dependence
Smoking-Cessation and Stimulant Treatment (S-CAST)
The primary objective of this study is to evaluate the impact of substance-abuse treatment as usual plus smoking-cessation treatment (TAU+SCT), relative to substance-abuse treatment as usual (TAU), on drug-abuse outcomes.
- Conditions
- Cocaine Dependence, Methamphetamine Dependence, Nicotine Dependence
- Trial name
- S-CAST (NCT01077024)
- Testing
- Smoking-cessation treatment
- Where
- 12 sites in United States
- Volunteers
- 538 people
- Sponsor
- University of Cincinnati
Schizophrenia, Substance Abuse
Screening Protocol for Research Participants
The Screening Protocol is a system devised to evaluate potential research participants for National Institute on Drug Abuse/Maryland Psychiatric Research Center (NIDA/MPRC) studies.
- Conditions
- Schizophrenia, Substance Abuse, Cocaine Abuse, Tobacco Use Disorder
- Trial name
- ScreenProt (NCT01010620)
- Testing
- Various Screening psychiatric and medical assessments
- Where
- United States
- Volunteers
- 523 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore